Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
739,250

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays

by Zacks Equity Research

PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.

Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes

by Zacks Equity Research

Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

by Zacks Equity Research

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

How Much Upside is Left in AMN Healthcare (AMN)? Wall Street Analysts Think 32%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 32% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What's in Store for Patterson Companies' (PDCO) Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.

Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout

by Zacks Equity Research

According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.

3 Reasons Why Growth Investors Shouldn't Overlook AMN Healthcare (AMN)

by Zacks Equity Research

AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.

ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany

by Zacks Equity Research

ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.

BD's (BDX) Latest Collaboration to Enhance Patient Care

by Zacks Equity Research

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.

Here's Why You Should Hold on to Ecolab (ECL) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

Charles River (CRL) to Create New Gene Therapy for Hemophilia A

by Zacks Equity Research

Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.

Align (ALGN) Hurt by Dental Practice Closures, FX Headwind

by Zacks Equity Research

Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout

by Zacks Equity Research

CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.

Humana (HUM) to Offer Home Care Model to Virginia's MA Members

by Zacks Equity Research

Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.

Here's Why Investors Should Retain Chemed (CHE) Stock Now

by Zacks Equity Research

Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

AMN Healthcare Services (AMN) Stock Moves -0.41%: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $100.27 in the latest trading session, marking a -0.41% move from the prior day.